Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Shares of hematologic and oncology concern Rigel Pharmaceuticals, Inc. ( RIGL ) have moved up sharply over the past month. The rally is being propelled by much better than expected Q3 results that posted earlierBret Jensen has over 13 y ...

Hello and welcome to Ask Before a Trend. I'm Josh Lipton and for the next half hour, we are breaking down the trends of today. Consumers began to show signs of cautious spending in September as retail sales rose modestly, increasing 0.2% in September as after a 0.6% gain August.But retailers feeling optimistic amid their holiday quarter as companies such as Abberrombi and Fitch, Best Buy, and Kohl's raising their fullear outlooks after topping third quarter expectations. So, how are consumers thinking of th ...

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trialAn independent Data Monitoring Committee (DMC) completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosingFollowing the DMC review, the study protocol will be updated, and topline results are now expect ...

VANCOUVER, BC / ACCESS Newswire / November 25, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce that it was invited to attend the University of Alberta's 2025 Innovation Awards in Edmonton, Alberta, which were held on November 21, 2025. The annual ceremony is meant to recognize outstanding research and innovation that can translate university discoveries into societal and commercial impact. ...

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Key Takeaways Sarepta shares rose after progress on its phase I/II SRP-1003 study for DM1.The company advanced dosing after a positive safety committee review of the program.The update also triggered a $200M milestone payment to Arrowhead under its licensing deal.Shares of Sarepta Therapeutics (SRPT) rose 7% on Monday after the company announced its progress on a phase I/II study evaluating SRP-1003, an investigational small interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1).While Sarep ...

The U.K.’s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc’s (NASDAQ:AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). • AUTL stock is showing exceptional strength. Get the market research here.Acute lymphoblastic leukemia is a cancer of the blood and bone marrow ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) Cohort 8 of ENDEAVOR (Study 9001-103). • SRPT shares are advancing steadily. Get the market research here.The purpose of Cohort 8 is to evaluate the use of an enhanced immunosuppressive regimen as part of treatment with Elevidys (delandistrogene moxeparvovec-rokl) for non-ambulant (patients who cannot walk) individuals with Duchenne muscular dystrophy.Data from Cohort 8 will be used to determi ...

Company Overview - Celcuity Inc. is a biotechnology company focused on developing diagnostic tests for cancer patients, aiming to identify effective therapies tailored to individual needs [1] Financial Performance - Celcuity's Return on Invested Capital (ROIC) is -36.46%, significantly lower than its Weighted Average Cost of Capital (WACC) of 4.88%, indicating negative returns on invested capital [2] - The ROIC to WACC ratio for Celcuity is -7.47, showing that returns are well below the cost of capital [2] Peer Comparison - Crinetics Pharmaceuticals has a ROIC of -42.35% and a WACC of 4.55%, resulting in a ROIC to WACC ratio of -9.30, which is less negative than Celcuity's, suggesting it is closer to covering its cost of capital [3] - Evelo Biosciences has a ROIC of -201.37% and a WACC of 9.04%, leading to a ROIC to WACC ratio of -22.28, indicating a more severe situation than Celcuity [4] - Scholar Rock Holding Corporation and Cue Biopharma report negative ROICs of -101.98% and -151.57%, respectively, with ROIC to WACC ratios of -15.01 and -15.31, reflecting a common trend among clinical-stage biotech companies facing negative returns due to high R&D investments and limited revenue generation [5]

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.The 200-day simple moving average is a useful tool for traders and analysts, establishing market trends for stocks, commodities, indexes, and other financial instruments over the long term. The marker moves higher or lower along with longer-term price moves, and serves as a support or resistance ...